136 related articles for article (PubMed ID: 37007083)
1. Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report.
Jiang H; Wang J; Deng W
Front Oncol; 2023; 13():1150931. PubMed ID: 37007083
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
4. Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report.
Cao X; Luo J; Zhao B; Fu H; Kang W
Front Immunol; 2022; 13():1036181. PubMed ID: 36544760
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.
Xu L; Qi Y; Jiang Y; Ji Y; Zhao Q; Wu J; Lu W; Wang Y; Chen Q; Wang C
Ann Transl Med; 2022 Mar; 10(6):325. PubMed ID: 35433940
[TBL] [Abstract][Full Text] [Related]
6. Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.
Jin H; Li P; Mao C; Zhu K; Chen H; Gao Y; Yu J
Onco Targets Ther; 2020; 13():1751-1756. PubMed ID: 32161470
[TBL] [Abstract][Full Text] [Related]
7. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
8. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
9. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
11. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
Xiang J; Gong W; Sun P; Wang X; Liu A
J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
[TBL] [Abstract][Full Text] [Related]
13. Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report.
Zhu Z; Dai PL; Han S; Qiu E; Wang Y; Li Z
Front Oncol; 2023; 13():1147636. PubMed ID: 37234987
[TBL] [Abstract][Full Text] [Related]
14. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
16. Intratumoral CD8
Tong G; Zhu M; Chen Y; Wang S; Cheng B; Wang S; Liao W
J Gastrointest Oncol; 2022 Aug; 13(4):1668-1678. PubMed ID: 36092315
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
18. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
Front Oncol; 2022; 12():867658. PubMed ID: 35669431
[TBL] [Abstract][Full Text] [Related]
19. Successful outcome of neoadjuvant PD-1 blockade, VEGFR-2 inhibitor plus chemotherapy for potentially unresectable esophagogastric junctional squamous cell carcinoma: a case report.
Chen KB; Wu ZW; Huang Y; Kang MX; Lin LL; Jiang SS; Zhang H; Huang YJ; Chen L
Transl Cancer Res; 2022 Sep; 11(9):3329-3336. PubMed ID: 36237240
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review.
Li X; Huang Q; Lei Y; Zheng X; Dai S; Leng W; Liu M
Ann Transl Med; 2021 Mar; 9(6):513. PubMed ID: 33850910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
